Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7,8-dihydroxy‑4‑phenyl‑2H‑chromen‑2-one is a synthetic coumarin derivative and neoflavone (neoflavonoid) with the molecular formula C₁₅H₁₀O₄ and a molecular weight of approximately 254.24 g/mol[6][10][1]. It features hydroxyl groups at positions seven and eight on the chromen ring and a phenyl group at position four. The compound is primarily used as an experimental research tool in phytochemical studies and as a reference standard for natural product analysis[6]. It exhibits antioxidant properties due to its vicinal dihydroxy groups[6], can inhibit Staphylococcus aureus DNA helicase activity[5], and has been reported as an inhibitor of catechol O-methyltransferase (COMT)[2]. There are no approved therapeutic indications or clinical trials beyond preclinical/experimental use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7,8-dihydroxy-4-phenyl-2H-chromen-2-one.